Background

Immunophenotypic analysis by multiparameter flow cytometry is a powerful tool in the evaluation of hematolymphoid neoplasia. Flow cytometry characterizes cells to classify disease, guide sequential testing, monitor efficacy of treatment (minimal residual disease) and rule out a reactive process.

At MPLN with a turnaround time of one day, flow cytometry is highly specific and sensitive for the evaluation of leukemia, lymphoma and other hematological abnormalities. Interdisciplinary testing on a single sample is reviewed closely to enhance the flow cytometry data; this includes clinical, morphologic, molecular, and genetic findings.

Resources

Flow Cytometry Information Sheet (DEC2018)

Flow Cytometry Tests

Bronchoalveolar Lavage (CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio)

Flow Cytometry Leukemia / Myeloma / Lymphoma

Leukocyte Adhesion Deficiency (CD11b, CD15, CD18) by FLOW*

Lymphocyte Analysis (T-cell subsets, CD19, CD56) by FLOW*

Paroxysmal Nocturnal Hemoglobinuria (PNH) - High Sensitivity by FLOW

T-cell Subsets (CD3, CD4, CD8, CD4:CD8 ratio) by FLOW*